# US 2026/0076985 A1 · Long-acting liposomal composition for treatment of pain in articular disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0076985 A1
- Document ID: US20260076985A1
- Status: Published application
- Kind: A1
- Application number: 19/400,777
- Filed: 2025-11-25
- Published: 2026-03-19
- Earliest claimed: 2023-01-19
- Assignees: Moebius Medical Ltd.
- Applicants: Moebius Medical Ltd.
- Inventors: Moshe WEINSTEIN; Ron PINKUS
- Web page: https://patentgrep.com/patent/US20260076985A1

## CPC

- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treating a subject having an articular disorder by administration of a long-acting liposomal composition. A preferred liposomal composition includes a phosphatidylcholine as the sole active ingredient, wherein the phosphatidylcholine is selected from the group consisting of 1,2-dimyristoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-dipentadecanoyl-sn-glycero-3-phosphocholine, 1,2-distearoyl-sn-glycero-3-phosphocholine, N-palmitoyl-D-erythro-sphingosylphosphorylcholine, and a combination thereof. The method provides a pain relief to the subject for at least 6 months which is manifested by a reduction from baseline or untreated control of at least 15 as determined by average of global pain achieved at about 26 weeks following administration.

## Claims

### Claim 1

A method of treating a subject having an articular disorder, the method comprising administration of a single intra-articular injection of a liposomal composition comprising a plurality of liposomes comprising a phospholipid as the sole active ingredient, wherein the phospholipid comprises a phosphatidylcholine selected from the group consisting of 1,2-dimyristoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-dipentadecanoyl-sn-glycero-3-phosphocholine, 1,2-distearoyl-sn-glycero-3-phosphocholine, N-palmitoyl-D-erythro-sphingosylphosphorylcholine, and a combination thereof, wherein the method comprises a reduction in Western Ontario and McMaster Universities Osteoarthritis Index A pain score of at least 50% compared to a baseline or untreated control, and wherein the method provides a pain relief to the subject for at least six months following administration.

### Claim 2 (depends on 1)

The method of claim 1, wherein the liposomal composition is administered once or every 4 to 12 months or more.

### Claim 3 (depends on 2)

The method of claim 2, wherein the liposomal composition is administered once in every four months, six months or 26 weeks.

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject has baseline Western Ontario and McMaster Universities Osteoarthritis Index A pain score≥2 and a Western Ontario and McMaster Universities Osteoarthritis Index A pain score reduction of at least 1 point.

### Claim 5 (depends on 1)

The method of claim 1, wherein the method comprises treating pain or irritation in a joint of the subject having an articular disorder.

### Claim 6 (depends on 5)

The method of claim 5, wherein the method further comprises a reduction in at least one of Western Ontario and McMaster Universities Osteoarthritis Index B stiffness score, Western Ontario and McMaster Universities Osteoarthritis Index C disability score, Patient Global Assessment of disease activity by visual analog scale, weekly average of daily global pain score by visual analog scale, weekly average of daily joint pain score by visual analog scale, cumulative amount of rescue medication used for pain relief, and urinary C-terminal crosslinking telopeptide of collagen Type II level, compared to baseline or untreated control.

### Claim 7 (depends on 6)

The method of claim 6, wherein the subject has baseline weekly average of daily joint pain score by visual analog scale ≥50 mm and a weekly average of daily joint pain score by visual analog scale reduction of at least 5, 10, 15, or 20.

### Claim 8 (depends on 7)

The method of claim 7, wherein the subject has baseline weekly average of daily joint pain score by visual analog scale in the range of from 50 mm to 90 mm.

### Claim 9 (depends on 1)

The method of claim 1, wherein the phosphatidylcholine concentration is about 50 mM to about 300 mM.

### Claim 10 (depends on 1)

The method of claim 1, wherein the liposomal composition comprises 1,2-dimyristoyl-sn-glycero-3-phosphocholine and 1,2-dipalmitoyl-sn-glycero-3-phosphocholine as the sole active ingredients.

### Claim 11 (depends on 10)

The method of claim 10, wherein the liposomal composition comprises 1,2-dimyristoyl-sn-glycero-3-phosphocholine and 1,2-dipalmitoyl-sn-glycero-3-phosphocholine in a mole ratio of 40:60 to 50:50; or wherein the liposomal composition comprises 1,2-dimyristoyl-sn-glycero-3-phosphocholine in a weight percent ranging from about 1% (w/w) to about 10% (w/w) and 1,2-dipalmitoyl-sn-glycero-3-phosphocholine in a weight percent ranging from about 2% (w/w) to about 12% (w/w); or wherein the liposomal composition comprises about 20 mg to about 700 mg of 1,2-dimyristoyl-sn-glycero-3-phosphocholine and about 30 mg to about 900 mg of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine.

### Claim 12 (depends on 1)

The method of claim 1, wherein the liposomal composition comprises a plurality of liposomes selected from the group consisting of small unilamellar vesicles, large unilamellar vesicles, giant unilamellar vesicles, oligolamellar vesicles, multilamellar vesicles, multivesicular liposomes, and a mixture or combination thereof; or wherein the liposomal composition comprises a plurality of liposomes in the form of multilamellar vesicles, and/or wherein the liposomes have sizes ranging from about 0.5 μm to about 10 μm.

### Claim 13 (depends on 1)

The method of claim 1, wherein the liposomal composition comprises a fluid medium comprising water or a buffer; and/or wherein the liposomal composition comprises a fluid medium comprising a histidine buffer; and/or wherein the liposomal composition has a pH in the range of about 5 to about 8.

### Claim 14 (depends on 13)

The method of claim 13, wherein the fluid medium further comprises a tonicity agent selected from a low molecular weight polyol and a sugar alcohol.

### Claim 15 (depends on 14)

The method of claim 14, wherein the polyol is selected from the group consisting of mannitol, sorbitol, glycerol, lactitol, maltitol, dextrose, lactose, trehalose, and combinations thereof; and/or wherein the weight ratio between the plurality of liposomes and the polyol ranges from about 6:1 to about 2:1.

### Claim 16 (depends on 13)

The method of claim 13, wherein the liposomal composition is administered at a volume of between about 0.5 ml and about 10 ml; or wherein the liposomal composition is administered at a volume of between about 1 ml and about 6 ml; or wherein the liposomal composition is administered at a volume of about 3 ml.

### Claim 17 (depends on 1)

The method of claim 1, wherein the articular disorder is osteoarthritis.

### Claim 18

A method of treating a subject having an articular disorder, the method comprising administration of a single intra-articular injection of a liposomal composition comprising a plurality of liposomes comprising a phospholipid as the sole active ingredient, wherein the phospholipid comprises a phosphatidylcholine selected from the group consisting of 1,2-dimyristoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-dipentadecanoyl-sn-glycero-3-phosphocholine, 1,2-distearoyl-sn-glycero-3-phosphocholine, N-palmitoyl-D-erythro-sphingosylphosphorylcholine, and a combination thereof, wherein the subject has baseline weekly average of daily joint pain score by visual analog scale ≥50 mm, wherein the method comprises a weekly average of daily joint pain score by visual analog scale reduction of at least 5 compared to a baseline or untreated control, and wherein the method provides a pain relief to the subject which is manifested by a reduction from baseline or untreated control of at least 15 as determined by average of global pain achieved at about 26 weeks following administration.

### Claim 19 (depends on 18)

The method of claim 18, wherein the liposomal composition is administered once or every 4 to 12 months or more.

### Claim 20 (depends on 18)

The method of claim 18, wherein the method comprises a weekly average of daily joint pain score by visual analog scale reduction of at least 25 compared to a baseline or untreated control.
